EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology

Abid A Anwar, Nidhi Jalan-Sakrikar, Robert C Huebert

Seminars in Liver Disease · 01.03.2025 · 45 (01) · 001-014

DOI: 10.1055/a-2490-1921 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Liver Disease, erschienen am 01.03.2025. Verfasst von Abid A Anwar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Liver Diseases, Liver, Genetic Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 141 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The field of ribonucleic acid (RNA) biology has revealed an array of noncoding RNA species, particularly long noncoding RNAs (lncRNAs), which play crucial roles in liver disease pathogenesis. This review explores the diverse functions of lncRNAs in liver pathology, including metabolic-associated steatotic liver disease, hepatocellular carcinoma, alcohol-related liver disease, and cholangiopathies such as primary sclerosing cholangitis and cholangiocarcinoma. We highlight key lncRNAs that regulate lipid metabolism, inflammation, fibrosis, and oncogenesis in the liver, demonstrating their diagnostic and therapeutic potential. Emerging RNA-based therapies, such as mRNA therapy, RNA interference, and antisense oligonucleotides, offer approaches to modulate lncRNA activity and address liver disease at a molecular level. Advances in sequencing technologies and bioinformatics pipelines are simultaneously enabling the identification and functional characterization of novel lncRNAs, driving innovation in personalized medicine. In conclusion, this review highlights the potential of lncRNAs as biomarkers and therapeutic targets in liver disease and emphasizes the need for further research into their regulatory mechanisms and clinical applications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingLiver DiseasesLiverGenetic TherapyHumansAnimals

Substanzen

RNA, Long Noncoding

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, Rochester, Minnesota.
  • Gastroenterology Research Unit, Mayo Clinic and Foundation, Rochester, Minnesota.
  • Mayo Clinic Center for Cell Signaling in Gastroenterology, Mayo Clinic and Foundation, Rochester, Minnesota.

Förderung

  • NIDDK NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Anwar, A. A., Jalan-Sakrikar, N., & Huebert, R. C. (2025). LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology. Seminars in Liver Disease, 45(01), 001-014. https://doi.org/10.1055/a-2490-1921

Vancouver

Anwar AA, Jalan-Sakrikar N, Huebert RC. LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology. Seminars in Liver Disease. 2025;45(01):001-014. doi:10.1055/a-2490-1921

BibTeX
@article{Anwar2025,
  author = {Anwar, Abid A and Jalan-Sakrikar, Nidhi and Huebert, Robert C},
  title = {LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology},
  journal = {Seminars in Liver Disease},
  year = {2025},
  volume = {45},
  number = {01},
  pages = {001--014},
  doi = {10.1055/a-2490-1921}
}
Kostenlos starten →